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coronary angiography
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Abstract
Background: Polymorphisms in the LPA gene were associated with coronary artery disease (CAD). However, there
are differences in the allelic frequencies, Lp(a) levels, and significant association with CAD according to ethnic
groups. In this scenario, the main aim of this study was to assess the influence of the LPA polymorphisms on
coronary lesions in Brazilian patients.
Methods: 1,394 consecutive patients submitted to coronary angiography to study suggestive CAD and twenty
coronary segments were scored. Genotyping for the LPA rs10455872 and rs3798220 polymorphisms were
performed by high resolution melting analysis.
Results: The frequencies of the rs10455872 G and rs3798220 C variant alleles were 6.4% and 6.2%, respectively. LPA
rs10455872 G variant allele was associated with higher odds ratio of having coronary lesions in an adjusted model
(OR = 2.02, 95% CI = 1.10-3.72, p = 0.02). Scores of coronary lesions (extension, severity, and Gensini scores) were
significantly different among rs10455872 genotype groups. Coronary lesions was not associated with LPA rs3798220
(OR = 1.09, 95% CI = 0.67-1.76, p = 0.73) and scores of coronary lesions were not different among rs3798220
genotypes.
Conclusions: We confirmed the association of the LPA rs10455872 with CAD in a large sample of Brazilian patients.
For the LPA rs3798220, our finding is consistent with studies which showed the lack of this genetic association.
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Introduction
Lipoprotein(a) [Lp(a)] is a plasma lipoprotein synthesized
by the liver that is composed of a low-density lipoprotein
(LDL) molecule, a high molecular weight glycoprotein
apolipoprotein(a), and a single molecule of apolipoprotein
(B). Physiological and pathogenic roles of Lp(a) remain
partially unknown. Studies have suggested that Lp(a) pro-
vides a link between the cholesterol transport and the fi-
brinolytic system acting as a modulator of the blood
clotting and fibrinolysis systems [1,2].
The increased concentration of Lp(a) has been associ-
ated with incidence and severity of cardiovascular dis-
ease (CVD), coronary artery disease (CAD), peripheral
artery disease, and stroke [3-7]. A meta-analysis of pub-
lished data from 31 prospective studies reported a rela-
tive risk for coronary heart disease of 1.60 (95% CI =
1.38-1.85) associated with Lp(a) levels [8,9].
More than 90% of the variance of Lp(a) concentration is
explained by genetic variation [1]. A genome-wide associ-
ation study showed that there is a group of genes strongly
associated with CAD, such as solute carrier family 22
member 3 (SLC22A3), lipoprotein(a)-like 2 (LPAL2), and
lipoprotein(a) (LPA), but investigators did not identify the
functional variants at these loci [10-12].
Two polymorphisms in the LPA gene (rs3798220 and
rs10455872) were associated with risk for CAD. How-
ever, there are differences in the allelic frequencies, Lp
(a) levels, and degree of association with CAD according
to ethnic groups [13-18]. In this scenario, the main aim
of this study was to assess the influence of the LPA
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polymorphisms on coronary lesions in Brazilian patients
submitted to coronary angiography.
Patients and methods
Patients submitted to coronary angiography
One thousand three hundred and ninety-four consecu-
tive patients submitted to coronary angiography to
study suggestive CAD were selected at the Laboratory
of Hemodynamic, Heart Institute (InCor), Sao Paulo,
Brazil. All patients had a clinical diagnosis of angina
pectoris and stable angina. No patient enrolled in this
study was currently experiencing an acute coronary syn-
drome. Patients with heart failure classes III–IV, hepatic
dysfunction, familiar hypercholesterolemia, previous
heart or kidney transplantation, and in antiviral treat-
ment were excluded [19,20]. All patients signed an in-
formed consent form and the protocol was approved by
the ethics committee from Hospital das Clínicas from
São Paulo University (CAPPesq 0398/04).
Demographic data and laboratory tests
Data regarding general characteristic, weight, height, race/
color, main cardiovascular risk factors (hypertension, dia-
betes, obesity, dyslipidemia, smoking, and current medical
treatment) were obtained by interview. Race/color was clas-
sified as White, Brown (Pardo in Portuguese; person with
admixture between White and Black), Black or Asiatic [21].
Triglycerides, total cholesterol (TC), high-density lipopro-
tein cholesterol, LDL cholesterol, and glucose were evalu-
ated by standard techniques in 12-h fasting blood samples.
Diabetes mellitus was diagnosed by the presence of fasting
glucose ≥ 126 mg/dL or the use of antidiabetic drugs [22].
Hyperlipidemia was defined as TC ≥ 240 mg/dL, LDL-C ≥
160 mg/dL, and/or use of lipid-lowering drugs [23].
Hemodynamic and angiographic data
Blood pressure was measured in the sitting position with
the use of a standard mercury sphygmomanometer on
the left arm after 5 min rest. The first and fifth phases of
Korotkoff sounds were used for systolic blood pressure
(SBP) and diastolic blood pressure (DBP), respectively.
The SBP and DBP were calculated from two readings
with a minimal interval of 10 min apart. Hypertension
was defined as mean SBP ≥140 mm Hg and/or DBP
≥90 mm Hg and/or antihypertensive drug use [24].
Twenty coronary segments were scored: each vessel
was divided into three segments (proximal, medial, and
distal), except for the secondary branches of the right
coronary artery (posterior ventricular and posterior de-
scending), which were divided into proximal and distal
segments. Stenosis higher than 50% in any coronary seg-
ment was graded 1 point and the sum of points for all
20 segments constituted the Extension Score. Lesion se-
verity was calculated as follows: none and irregularities, 0
points; <50%, 0.3 points; 50–70%, 0.6 points; >70–90%, 0.8
points; and >90–100%, 0.95 points. The Severity Score
was calculated through the sum of points for all 20 coron-
ary segments [25].
Genotyping
Genomic DNA from subjects was extracted from periph-
eral blood following standard salting-out procedure.
Additional file 1: Figure S1 shows genotyping detected
by polymerase chain reaction (PCR) followed by high
resolution melting (HRM) analysis with the Rotor Gene
6000® instrument (Qiagen, Courtaboeuf, France). The
QIAgility® (Qiagen, Courtaboeuf, France), an automated
instrument, was used according to instructions to
optimize the sample preparation step [26].
Amplification of the fragment for the LPA rs10455872
(A > G, intron 25) polymorphism was performed using
the primer sense 5′- ATGGGCTGGCAACACATAG -
3′ and antisense 5′- CACTTTCTCCTCTAACCTGTA
TAA -3′ (78 pairs base). Amplification of the fragment
for the LPA rs3798220 (T > C, p.Ile1891Met) poly-
morphism was performed using the primer sense 5′-
GGCTCCAAGAACAGCCTAGA -3′ and antisense
5′- TCCTCAAGGCCTTCATCCTA -3′ (104 pairs base).
A 40-cycle PCR was carried out with the following condi-
tions: denaturation of the template DNA for first cycle of
94°C for 120 s, denaturation of 94ºC for 20 s, annealing of
56.7°C for 20 s, and extension of 72°C for 22 s. PCR was
performed with addition of fluorescent DNA-intercalating
SYTO9® (1.5 μM; Invitrogen, Carlsbad, USA). In the HRM
phase, the Rotor Gene 6000® measured the fluorescence in
each 0.1°C temperature increase in the range of 72-81°C.
Melting curves were generated by the decrease in fluores-
cence with the increase in the temperature; and in ana-
lysis, nucleotide changes result in three different curve
patterns (Additional file 1: Figure S1). Samples of the
three observed curves were analyzed using bidirectional
sequencing as a validation procedure (ABI Terminator
Sequencing Kit® and ABI 3500XL Sequencer® - Applied
Biosystems, Foster City, CA, USA) [27]. The two methods
gave identical results in all tests. The wild-type, heterozy-
gous and mutant homozygous genotypes could be easily
discernible by HRM analysis. In addition, 4% of the sam-
ples were randomly selected and reanalyzed as quality
controls and gave identical results.
Statistical analysis
Categorical variables are presented as percentage while
continuous variables are presented as mean ± standard de-
viation. Chi-square test was performed for comparative
analysis of general characteristics and coronary lesion fre-
quency according to LPA polymorphisms. Dominant
models (AG+GG) for the rs10455872 or (TC +CC) for
the rs3798220 were performed because the frequencies of
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the GG and CC homozygous genotypes are low. Student’s
t-test was performed for comparing the age, body mass
index (BMI), biochemical data, blood pressures, and angio-
graphic data means according to LPA polymorphisms. Bio-
chemical data, blood pressures, and angiographic data were
adjusted for age, gender, and race/color. Logistic regression
univariate and multivariate analyses were performed to
evaluate OR (odds ratio) for coronary lesions. Two adjusted
models were performed: one using age, gender, and race/
color and another with the additional covariates BMI,
hyperlipidemia, statin use, and smoking. Linkage disequilib-
rium, Hardy-Weinberg equilibrium, and haplotype analyses
were conducted with Haploview 4.0. All statistical analyses
were carried out using the SPSS software (v. 16.0), with the
level of significance set at p ≤ 0.05.
Results
General characteristics and LPA polymorphisms
Of the 1,394 patients, mean age of 59.7 ± 10.4, 1,126
(80.8%) had coronary lesions indicated by coronary
angiography. The frequency of the rs10455872 G variant
allele was 6.4% and the distribution of the genotypes was
0.6% (n = 8) for variant homozygous, 11.7% (n = 163) for
heterozygous and 87.7% (n = 1223) for wild-type. The fre-
quency of the rs3798220 C variant allele was 6.2% and the
distribution of the genotypes was 0.4% (n = 6) for variant
homozygous, 11.6% (n = 165) for heterozygous and 88.0%
(n = 1248) for wild-type. The genotypic distribution for
the LPA rs10455872 and rs3798220 polymorphisms
were in accordance with the Hardy–Weinberg equilibrium
(X2 = 1.01, p = 0.31 and X2 = 0.05, p = 0.82, respectively).
Linkage disequilibrium analysis shows that the LPA
rs3798220 and rs10455872 variant alleles had no strong
disequilibrium (LD = 73) (Additional file 2: Figure S2).
Biochemical, hemodynamic, and angiographic data
according to LPA rs10455872 polymorphism
Table 1 shows data from patients submitted to coronary
angiography according to LPA rs10455872 genotypes.
The frequency of the LPA rs10455872 AG or GG geno-
types was lower in non-Whites compared with Whites
(p = 0.02). Patient carrying AG or GG genotypes had
higher TC mean and proportion of hyperlipidemia. Re-
garding the angiographic data, higher frequency of coron-
ary lesions (p = 0.004) was found in patients with AG or
GG genotypes (88.9%) compared to patient with AA geno-
type (79.6%). Also, scores of coronary lesions (extension,
severity, and Gensini scores) were significantly different
among genotype groups (p < 0.001, p < 0.001, and p = 0.05,
respectively) (Table 1).
Furthermore, the presence of the LPA rs10455872 G vari-
ant allele was associated with higher OR of having coronary
lesion, which we compared normal coronary arteries versus
one-vessel, two-vessel, and three-vessel disease. Table 2
shows three models, being the OR of 2.02 (95% CI = 1.10-
3.72, p = 0.02) in an adjusted model with age, gender, race/
color, BMI, hyperlipidemia, statin use, and smoking. Also,
Additional file 3: Table S1 shows logistic regression univari-
ate analysis of the OR for coronary lesions. Additional file
4: Table S2 shows significant association for the variables
age (as a continuous variable presented in the Table or as
categorical variable - median age of 61 years as a cut-off –
resulting in an OR of 1.88, 95% CI = 1.43-2.47, p < 0.001),
gender, BMI, statin use, and hyperlipidemia in a logistic re-
gression multivariate analysis.
Analysis stratified by race for the LPA rs10455872
polymorphism
In the White group (n = 901), patients with AG or GG ge-
notypes (n = 128) had higher frequency of coronary lesions
Table 1 General characteristics, biochemical,
hemodynamic, and angiographic data according to LPA
rs10455872 genotypes in the patients submitted to
coronary angiography
Genotypes p value
(n=1394, 100%) AA
(n=1223)
AG+GG
(n=171)
Age (years) 59.9 ± 10.1 59.5 ± 10.8 0.62
Gender, female (%) 40.6 37.4 0.42
Race/color (%)
White 65.0 74.9
Intermediate 29.8 23.4 0.02
Black 5.2 1.8
Hypertension (%) 70.0 68.4 0.68
Diabetes (%) 31.2 27.5 0.33
Hyperlipidemia (%) 57.2 71.3 0.002
Statin use (%) 28.0 30.5 0.61
Smokers (%) 35.6 38.0 0.44
Body mass index (Kg/m2) 27.7 ± 4.8 27.6 ± 4.9 0.99
Total cholesterol (mg/dL) 228 ± 49 237 ± 46 0.05
LDL-C (mg/dL) 147 ± 44 155 ± 39 0.11
HDL-C (mg/dL) 42 ± 12 42 ± 10 0.82
Triglycerides (mg/dL) 183 ± 130 179 ± 108 0.75
Systolic blood pressure (mmHg) 149 ± 34 152 ± 39 0.61
Diastolic blood pressure (mmHg) 82 ± 15 84 ± 15 0.29
Ejection fraction (%) 60.6 ± 14.4 56.8 ± 17.7 0.07
Coronary lesions (%) 79.6 88.9 0.004
Extension score 2.1 ± 1.6 2.6 ± 1.7 <0.001
Severity score 1.5 ± 1.2 1.9 ± 1.3 <0.001
Gensini score 19.7 ± 28.2 25.7 ± 32.0 0.05
HDL-C: high density lipoprotein; LDL-C: low density lipoprotein.
Biochemical data, blood pressures, and angiographic scores were adjusted for
age, gender, and race/color.
Coronary lesions frequency was compared between normal coronary arteries
versus one-vessel, two-vessel, and three-vessel disease.
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compared to patient with AA genotype (n = 773) (90.6%
and 81.0%, respectively, p = 0.008). The presence of the
LPA rs10455872 G variant allele was associated with
higher OR of having coronary lesion in an adjusted model
(OR = 2.17, 95% CI = 1.04-4.61, p = 0.03). Also, scores of
coronary lesions were significantly different among geno-
type (extension: 2.7 ± 1.6 and 2.2 ± 1.6; severity: 1.9 ± 1.3
and 1.6 ± 1.2; and Gensini scores: 26.3 ± 30.0 and 19.7 ±
29.8) (p = 0.001, p = 0.01, and p = 0.04, respectively).
In the non-White group (n = 460, formed for Black and
Brown individuals), frequency of coronary lesions was not
statistically different (83.7% for AG or GG genotypes and
77.0% for AA genotype, p = 0.30). However, the presence of
the G variant allele was associated with higher OR (OR =
1.95, 95% CI = 1.09-4.39, p = 0.04 – adjusted model) and
scores of coronary lesions were different between AG or
GG and AA genotypes (extension score: 2.6 ± 1.7 and 2.0 ±
1.6; and severity score: 1.9 ± 1.3 and 1.4 ± 1.2) (p = 0.04, and
p = 0.03, respectively). Gensini score was marginally
different between genotypes (24.7 ± 29.6 and 21.2 ± 27.5;
p = 0.06).
Biochemical, hemodynamic, and angiographic data
according to LPA rs3798220 polymorphism
The proportion of hyperlipidemia was not different
among rs3798220 genotypes (p = 0.62). Regarding the
angiographic data, the frequency of coronary lesions
was not associated with rs3798220 (p = 0.57) and no sig-
nificant OR was observed in an adjusted model (OR =
1.09, 95% CI = 0.67-1.76, p = 0.73). Also, scores of cor-
onary lesions (extension, severity, and Gensini scores)
were not significantly different among genotype groups
(p = 0.85, p = 0.56, and p = 0.46, respectively).
Discussion
The two LPA polymorphisms studied in this study are
some of the most important genetic markers for CAD.
In this context, our main finding was that the LPA
rs10455872 polymorphism is associated with coronary
lesions in Brazilian patients submitted to coronory
angiography. On the other hand, no association for the
LPA rs3798220 was observed for any of the tested
phenotypes.
Studies have reported higher Lp(a) concentration in
sub-Saharan African descent and lower Lp(a) concentra-
tion in European descent [13,15,28,29]. Regarding the
ethnicity, Brazil has one of the most heterogeneous
population of the world, composed by a mixture of dif-
ferent ethinic groups, mainly European descent, African
descent and Amerindians. In our data, a stratified ana-
lysis by race supported a role for the rs10455872 poly-
morphism independent of ethnic group.
Corroboring with our study, Anderson et al. found that
the rs10455872 polymorphism strongly predicted preva-
lent CAD (per allele OR = 1.43, 95% CI = 1.07-1.91) [30].
Helgadottir et al. showed that patients with CAD carrying
LPA risk alleles have increased susceptibility to athero-
sclerotic manifestations outside of the coronary tree and
they are more likely to be diagnosed earlier with CAD
than are CAD cases not carrying this variant [31]. Other
studies that analyzed the rs10455872 and rs3798220 poly-
morphisms together reported an increased risk of coron-
ary disease and Lp(a) level that can be explained by these
LPA polymorphisms [11,32]. LPA rs10455872 is an in-
tronic polymorphism associated with short KIV-2 repeat
region (kringle IV type 2) which is associated with Lp(a)
levels. In the present study, the frequency of the
rs10455872 G variant allele was 6.4% for overall, but we
observed higher allelic frequency in White compared with
non-White groups. The association of the rs10455872
with CAD was significant even in the non-White group
which had a small sample size. These data suggest that
rs10455872 is also a strong genetic marker for CAD risk
in ethnically mixed populations.
For the LPA rs3798220 polymorphism, we did not ob-
serve significant association with coronary lesions. Data
from other studies also did not support a relationship be-
tween this LPA variant and CAD [33,34]. Furthermore,
Anderson et al., studying 1,400 participants with coronary
angiography (more than 90% Whites), did not find an as-
sociation signal between rs3798220 and CAD (OR = 1.47,
95% CI = 0.81-2.67, p = 0.20) [30]. In contrast to our study,
the rs3798220 has previously been reported to have an as-
sociation with the Lp(a) level and the risk of coronary dis-
ease [35-37]. LPA rs3798220 results in an aminoacid
substitution in the protease domain of LPA, but it can not
provide stronger association than rs10455872 which might
be representating a more complex group of genetic vari-
ants or repeat structures. A possible hypothesis for the
lack of this association in the present study could be the
lower value of linkage disequilibrium between rs3798220
and rs10455872 identified in the Brazilian patients com-
pared with some studies with patients predominantly from
European descent [11,35-37]. Another hypothesis may be
low statistical power, but less likely if the impact of
Table 2 Analysis of the coronary lesions odds ratio
associated with LPA rs10455872 AG or GG genotypes in
the patients submitted to coronary angiography
(n=1394, 100%) OR 95% CI p value
Models
Unadjusted 2.04 1.24-3.36 0.005
Adjusted* 2.05 1.22-3.43 0.006
Adjusted** 2.02 1.10-3.72 0.02
Coronary lesions frequency was compared between normal coronary arteries
versus one-vessel, two-vessel, and three-vessel disease.
*Adjusted for age, gender, and race/color.
**Adjusted for age, gender, race/color, body mass index, hyperlipidemia, statin
use, and smoking.
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rs3798220 was approximately equal to the impact of
rs10455872. However, the exact reason is unclear and
other genetic components differently expressed due to
ethnicity might be important modulators.
The exact mechanism by which an increased Lp(a)
level increases the CAD risk is not fully understood.
Pathways modulated by Lp(a) may involve the LDL-
cholesterol transport system, the inhibition of the ex-
pression of tissue factor, the inhibition of conversion of
plasminogen to plasmin, the carriage of pro-inflammatory
oxidized phospholipids, and an atherosclerotic stenotic
mechanism [30,38-44]. Some studies reported that the se-
verity of coronary artery disease is associated with Lp(a)
levels or LDL concentration [45-48]. Regarding to the Lp(a)
level as a risk factor in different ethnic groups, Lp(a) has
been associated with risk in European populations [1], but
not unequivocally in African Americans [17,18]. However,
a recent study identified that the increased risk of CVD
was at least as strong in African Americans as in White
Americans [49]. Another study investigated differential
frequencies of LPA polymorphisms in non-Hispanic
whites, non-Hispanic blacks, and Mexican Americans
[50]. Interestingly, 15 of the 19 polymorphisms tested
were strongly associated with Lp(a) levels in at least one
subpopulation, six in at least two subpopulations, and
none in all three subpopulations. The lack of gene-
ralization of associations across ethnicities suggests that
specific LPA variants may be contributing to the observed
Lp(a) between-population variance. Authors also com-
pared the allele frequencies in HapMap, and observed ex-
tremely high correlations (r ≥ 0.99) in allele frequencies
between non-Hispanic whites and HapMap CEU (US
individuals of northern and western European ancestry)
and between non-Hispanic blacks and both HapMap YRI
(Yoruba from West Africa) and ASW (individuals with
African ancestry from the Southwest USA) [50].
There are some limitations in our study. First, we did
not measure Lp(a) levels and we also did not genotype
KIV-2 repeats to check their association with both the
LPA polymorphisms and/or the CAD phenotype. Sec-
ond, we did not assess ancestry through genetic markers;
instead, we used a self-declared classification which is
commonly applied in Brazil and correlates with genetic
ancestry determination. In addition, in our stratified ana-
lysis by race, we observed significant association of the
rs10455872 with CAD in the White and non-White pa-
tient groups. Third, our plaque burden data are derived
from institutional records and represent real-life data, as
opposed to core-lab derived hemodinamic data. Thus,
and despite the greater external validity of our results,
we were not able to determine inter- or intra-observed
variability estimates. In addition, our choosen method
for establishing atherosclerotic burden in the studied pa-
tients has relied upon the Gensini Score, which has been
shown to highly correlate with this end-point. Other
scores could also be used, although they are not as well
fitted for quantifing plaque burden. One example is the
Syntax score, an angiographic tool for grading the com-
plexity of CAD and designed to better anticipate the
risks of percutaneous or surgical revascularization. Fin-
naly, it is not possible to completely exclude the inter-
action of the covariates as other genetic markers, use of
concomitant drugs, ethnicity, gender and age on our
findings [51-54]. Nonetheless, our findings remained
after multivariate analysis.
Conclusions
In conclusion, we confirmed the association of the LPA
rs10455872 with CAD in a large sample of Brazilian pa-
tients. For the LPA rs3798220, our finding is consistent
with studies which showed the lack of this genetic
association.
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